**PROGRAF®**
0.5 mg, 1 mg, 5 mg Capsules &
5 mg/mL Concentrated Injection

**PROGRAF® XL**
0.5 mg, 1 mg, 5 mg Prolonged-Release Capsules

**PRODUCT INFORMATION**

**NAME OF THE MEDICINE**

Tacrolimus

\[
5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-
hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-
(2-propenyl)-15,19-epoxy-3H-pyrido [2,1-c] [1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-
tetrone, monohydrate.
\]

Molecular Formula: C\textsubscript{44}H\textsubscript{69}NO\textsubscript{12}.H\textsubscript{2}O
Molecular Weight: 822.03. CAS 104987-11-3

**DESCRIPTION**

Tacrolimus appears as white crystals or a crystalline powder, very soluble in methanol, and
chloroform, freely soluble in acetone and ethanol and practically insoluble in hexane and
water. Tacrolimus is obtained by fermentation as a single enantiomer but exists in tautomeric
equilibration in aqueous solution.
PROGRAF capsules also contain hypromellose 2910, cellulose, croscarmellose sodium, lactose and magnesium stearate. The capsule shell contains gelatin, purified water and titanium oxide and a dye (ferric oxide yellow E172 for 0.5 and 1 mg capsules, and ferric oxide red E172 for 5 mg capsules). The capsules have a trace of printing ink (that used in the 0.5 and 1 mg capsules contains shellac, soya lecithin, dimethylpolysiloxane and ferric oxide red E172; that used in the 5 mg capsules contains shellac, propylene glycol and titanium dioxide E171).

PROGRAF-XL prolonged-release capsules contain hypromellose, ethylcellulose, lactose and magnesium stearate. The capsule shells contain gelatin, titanium dioxide, iron oxide yellow CI77492, iron oxide red CI77491 and sodium lauryl sulfate. The capsules also have a trace of printing ink, Opacode S-1-15083 red, which contains shellac, soya lecithin, simethicone and iron oxide red CI77491.

PROGRAF Concentrated Injection contains PEG-60 Hydrogenated Castor Oil and Ethanol.

**PHARMACOLOGY**

Tacrolimus is a macrolide lactone with potent *in vitro* and *in vivo* immunosuppressive activity. Studies suggest that tacrolimus inhibits the formation of cytotoxic lymphocytes which are regarded as being primarily responsible for graft rejection. Tacrolimus suppresses T-cell activation and T-helper-cell-dependent B-cell proliferation, as well as the formation of lymphokines such as interleukins-2 and -3 and gamma-interferon and the expression of the interleukin-2 receptor. At the molecular level, the effects of tacrolimus appear to be mediated by binding to a cytosolic protein (FKBP), which is responsible for the intracellular accumulation of the compound. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is formed and the phosphatase activity of calcineurin inhibited.

Studies in animals and man have shown that PROGRAF is able to prevent and treat graft rejection following transplantation of the liver, kidney, and other solid organs.

**PHARMACOKINETICS**

**Absorption**

In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract. Available tacrolimus is generally rapidly absorbed. Following oral administration of PROGRAF capsules peak concentrations \(C_{\text{max}}\) of tacrolimus in blood are achieved in approximately 1 - 3 hours. PROGRAF-XL is a prolonged-release formulation of tacrolimus resulting in an extended oral absorption profile with an average time to \(C_{\text{max}}\) of approximately 2 hours. In some patients, tacrolimus appears to be continuously absorbed over a prolonged period yielding a relatively flat absorption profile. The mean oral bioavailability of PROGRAF is in the range of 20% - 25%.

After oral administration (0.30 mg/kg/day) to liver transplant patients, steady-state concentrations of PROGRAF were achieved within 3 days in the majority of patients. In healthy subjects, PROGRAF 0.5 mg, PROGRAF 1 mg and PROGRAF 5 mg capsules have been shown to be bioequivalent, when administered as equivalent dose.

The rate and extent of absorption of tacrolimus is greatest under fasted conditions. The presence of food decreases both the rate and extent of absorption of tacrolimus, the effect being most pronounced after a high-fat meal. The effect of a high-carbohydrate meal is less pronounced.

In stable liver transplant patients, the oral bioavailability of PROGRAF was reduced when it was administered after a meal of moderate fat (34% of calories) content. Decreases in AUC (27%) and \(C_{\text{max}}\) (50%), and an increase in \(t_{\text{max}}\) (173%) in whole blood were evident.
In a study of stable renal transplant patients who were administered PROGRAF immediately after a standard continental breakfast the effect on oral bioavailability was less pronounced. Decreases in AUC (2 to 12%) and C<sub>max</sub> (15 to 38%), and an increase in t<sub>max</sub> (38 to 80%) in whole blood were evident. Bile flow does not influence the absorption of PROGRAF. A strong correlation exists between AUC and whole blood trough levels at steady-state for PROGRAF and PROGRAF-XL. Monitoring of whole blood trough levels therefore provides a good estimate of systemic exposure.

**Distribution and elimination**

In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic. In the systemic circulation, tacrolimus binds strongly to erythrocytes resulting in an approximate 20:1 distribution ratio of whole blood/plasma concentrations. In plasma, tacrolimus is highly bound (> 98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.

Tacrolimus is extensively distributed in the body. The steady-state volume of distribution based on plasma concentrations is approximately 1300 l (healthy subjects). Corresponding data based on whole blood averaged 47.6 l.

Tacrolimus is a low-clearance substance. In healthy subjects, the average total body clearance (TBC) estimated from whole blood concentrations was 2.25 l/h. In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed. Paediatric liver transplant recipients have a TBC approximately twice that of adult liver transplant patients. Factors such as low haematocrit and protein levels, which result in an increase in the unbound fraction of tacrolimus, or corticosteroid-induced increased metabolism are considered to be responsible for the higher clearance rates observed following transplantation.

The half-life of tacrolimus is long and variable. In healthy subjects, the mean half-life in whole blood is approximately 43 hours. In adult and paediatric liver transplant patients, it averaged 11.7 hours and 12.4 hours, respectively, compared with 15.6 hours in adult kidney transplant recipients. Increased clearance rates contribute to the shorter half-life observed in transplant recipients.

**Metabolism and biotransformation**

Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4. Tacrolimus is also considerably metabolised in the intestinal wall. There are several metabolites identified. Only one of these has been shown in vitro to have immunosuppressive activity similar to that of tacrolimus. The other metabolites have only weak or no immunosuppressive activity. In systemic circulation only one of the inactive metabolites is present at low concentrations. Therefore, metabolites do not contribute to pharmacological activity of tacrolimus.

**Excretion**

Following intravenous and oral administration of <sup>14</sup>C-labelled tacrolimus, most of the radioactivity was eliminated in the faeces. Approximately 2% of the radioactivity was eliminated in the urine. Less than 1% of unchanged tacrolimus was detected in the urine and faeces, indicating that tacrolimus is almost completely metabolised prior to elimination: bile being the principal route of elimination.

**Pharmacokinetics in special populations**

The pharmacokinetics of tacrolimus in special populations have not been studied in detail. See DOSAGE AND ADMINISTRATION for dose adjustments in special populations.
CLINICAL TRIALS

PROGRAF

Liver
The efficacy and safety of a PROGRAF based immunosuppressive regimen following orthotopic liver transplantation was assessed in two prospective, randomised, non-blinded multicentre trials. The active control groups were treated with a cyclosporin based regimen. In a European trial, patients received a tacrolimus-steroid based regimen (n=264) or a cyclosporin-azathioprine-steroid (with or without anti-lymphocyte globulin) based regimen (n=265).

Equivalent graft survival (77.5 vs 72.69%) and patient survival (82.9 vs 77.5%) was seen. Significant reductions were seen in the tacrolimus treated patients for incidence of acute rejection (40.5 vs 49.8%), refractory acute rejection (0.8 vs 5.3%) and chronic rejection (1.5 vs 5.3%). In American trial patients received a tacrolimus-steroid regimen (n=263) or a cyclosporin (mainly triple therapy) based regimen (n=266). Equivalent graft survival (82 vs 79%) and patient survival (88 vs 88%) rates were observed. Tacrolimus was associated with significant reductions in the incidence of acute rejection (68 vs 76%), steroid resistant rejection (19 vs 36%) and refractory rejection (3 vs 15%).

Kidney
Two randomised, multicentre non-blinded comparative trials were performed in cadaveric kidney transplantation. In an American trial patients received a tacrolimus based (n=205) or cyclosporin based (n=207) regimen. All patients also received maintenance azathioprine and corticosteroids and an induction course of an antilymphocyte antibody preparation. Equivalent graft survival (91.2 vs 87.9%) and patient survival (95.6 vs 96.6%) was seen for the tacrolimus and cyclosporin treated patients respectively. A significantly reduced one year incidence rate of biopsy confirmed acute rejection (30.7 vs 46.4%), moderate to severe acute rejection (10.7 vs 26.6%) and use of antilymphocyte antibody preparation for treatment of rejection (10.7 vs 25.1%) was seen in the tacrolimus treated patients.

A European trial compared triple drug based immunosuppression with tacrolimus or cyclosporin centred regimens, with 303 and 145 patients randomised to the tacrolimus and cyclosporin arms respectively. Equivalent one year graft survival (82.5 vs 86.2%) and one year patient survival (93.0 vs 96.5%) rates were observed, but with significantly reduced one year acute rejection rate (32.3 vs 54.5%), rate of corticosteroid sensitive rejections (24.4 vs 42.1%) and rate of corticosteroid resistant rejections (10.2 vs 20.7%).

Heart
Two open-label, randomized, comparative studies evaluated the safety and efficacy of tacrolimus-based and cyclosporin-based immunosuppression in primary orthotopic heart transplantation. In a Phase 3 study conducted in Europe, 314 patients received a regimen of antibody induction, corticosteroids and azathioprine in combination with tacrolimus or cyclosporin modified for 18 months. In a 3-arm study conducted in the US, 331 patients received corticosteroids and tacrolimus plus sirolimus, tacrolimus plus mycophenolate mofetil (MMF) or cyclosporin modified plus MMF for 1 year.

In the European Phase 3 study, patient / graft survival at 18 months post-transplant was similar between treatment arms, 91.7% in the tacrolimus group and 89.2% in the cyclosporin group. In the US study, patient and graft survival at 12 months was similar with 93.5% survival in the tacrolimus plus MMF group and 86.1% survival in the cyclosporin modified plus MMF group. In the European study, the cyclosporin trough concentrations were above the pre-defined target range (ie 100-200 ng/mL) at Day 122 and beyond in 32-68% of the patients in the cyclosporin treatment arm, whereas the tacrolimus trough concentrations were
within the pre-defined target range (ie. 5-15 ng/mL) in 74-86% of the patients in the tacrolimus treatment arm.

The US study contained a third arm of a combination regimen of sirolimus, 2mg per day, and full-dose tacrolimus; however, this regimen was associated with increased risk of wound healing complications, renal function impairment, and insulin dependent post transplant diabetes mellitus, and is not recommended in de novo heart transplant patients (see PRECAUTIONS).

**Lung**

In a prospective, 2-centre, open-label randomized trial, 74 lung transplant patients (aged 20-66 years old) were randomised to tacrolimus-based (n=37) and cyclosporin-based (n=37) immunosuppression. The drugs were given in combination with mycophenolate mofetil and corticosteroids. Tacrolimus was started immediately after transplantation as continuous intravenous infusion at a dose of 0.015mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/mL in the first month and 9 to 12 ng/mL thereafter. The 6-months and 1-year patient survival data was similar in both groups (89% vs 84% and 82% vs 71%, cyclosporin vs tacrolimus respectively). Freedom from acute rejection was comparable at 1 year, 35% in the cyclosporin group and 46% in the tacrolimus group.

Another prospective, randomised, open-label study included 66 patients on tacrolimus versus 67 patients on cyclosporin, aged 20 to 66 years old. The drugs were given in combination with azathioprine and corticosteroids. Tacrolimus was started 6 to 8 hours after transplantation as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/mL. The 1-year patient survival was 83% in the tacrolimus group and 71% in the cyclosporin group, the 2-year survival rates were 76% and 66%, respectively. The differences between groups were not statistically significant. Freedom from acute rejection after at least 37 weeks follow-up was also comparable (14% in the tacrolimus group and 11.5% in the cyclosporin group).

A number of published, open, uncontrolled studies have examined the use of tacrolimus in lung transplant patients who have developed refractory acute rejection or bronchiolitis obliterans syndrome while receiving cyclosporin-based immunosuppressive regimens. In these studies, conversion from cyclosporin to tacrolimus has been associated with improved clinical outcomes such as reduced frequency of further acute rejection episodes and stabilisation or improvement in declining FEV₁ values.

**PROGRAF XL**

Three Phase III non-inferiority studies have been conducted, confirming the safety and efficacy of PROGRAF XL is comparable to PROGRAF in de novo kidney transplant patients aged 12 years and older (n=638 and 667) and de novo liver transplant patients aged 18 years and older (n=471). Patient survival and graft survival at 1 year post transplant ranged from 91% to 99%. In these studies tacrolimus was used in combination with corticosteroids (liver transplant), with corticosteroids and mycophenolate mofetil (kidney), or with corticosteroids, mycophenolate mofetil and basiliximab (kidney).

The results of all conversion studies demonstrate that conversion from PROGRAF-based immunosuppression regimens to PROGRAF XL-based immunosuppression regimens on 1:1 (mg:mg) basis has been performed in adult kidney, liver and heart transplant recipients without any increase in incidences of acute rejection, graft loss or effects on patient survival rates. Long-term following up of patients in the conversion studies (up to 2 years) confirm patient survival and graft survival with PROGRAF XL were consistent across all conversion studies, ranging from 97% to 100%.
INDICATIONS

Indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

CONTRAINDICATIONS

Tacrolimus is contra-indicated in patients hypersensitive to tacrolimus or other macrolides, or to other ingredients of the capsules.

PROGRAF Concentrated Injection should not be used in patients known to be hypersensitive to polyoxyethylene hydrogenated castor oils.

PRECAUTIONS

Tacrolimus therapy requires careful monitoring in hospital units equipped and staffed with adequate laboratory and supportive medical resources. The drug should only be prescribed, and changes in immunosuppressive therapy should be initiated, by physicians experienced in immunosuppressive therapy and the management of transplant patients. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Post Transplant Diabetes Mellitus (PTDM)

Post transplant insulin dependent diabetes mellitus (PTDM - use of insulin for 30 or more consecutive days, with < 5 day gap, by patients without a prior history of insulin or non insulin-dependent diabetes mellitus) was reported in 20% (30/151) and 6% (17/281) of PROGRAF treated kidney transplant patients in the U.S. and European randomised trials respectively. The median time to onset of PTDM was 68 days. Insulin dependence was reversible in 15% of these patients at one year and in 50% at two years post transplant. Black and Hispanic patients were found to be at increased risk of development of PTDM in the U.S. trial. The risk benefit ratio should be carefully considered before using tacrolimus in kidney transplant patients with a pre-transplant diabetic condition.

In liver transplantation PTDM was reported in 18% (42/239) and 11% (26/239) of PROGRAF treated patients and was reversible in 45% and 31% of these patients at one year post transplant in the U.S. and European randomised trials respectively.

Insulin-dependent post-transplant diabetes mellitus was reported in 13% (10/75) and 22% (29/132) of PROGRAF-treated heart transplant patients receiving mycophenolate mofetil or azathioprine and was reversible in 30% and 17% of these patients at one year post transplant, in the US and European randomised studies, respectively.

Neurotoxicity

Neurological and CNS disorders have been reported with PROGRAF therapy. Symptoms include tremor, headache, changes in motor function, sensory function or mental status, insomnia, seizures, coma and delirium. Patients experiencing such events should be carefully monitored. In cases of severe or worsening neurological disorder, adjustment of the immunosuppressive regimen should be considered.

Posterior reversible encephalopathy syndrome (PRES)

Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If patients taking tacrolimus present with symptoms indicating PRES such as headache, altered mental status, seizures, and visual disturbances, a
radiological procedure (e.g. MRI) should be performed. If PRES is diagnosed, adequate blood pressure and seizure control and immediate discontinuation of systemic tacrolimus is advised. Most patients completely recover after appropriate measures are taken.

**Pure red cell aplasia (PRCA)**

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease or concomitant medications associated with PRCA.

**Nephrotoxicity**

Tacrolimus can cause renal impairment characterized by increases in serum creatinine as a result of a reduced glomerular filtration rate, particularly when used in high doses. These changes have been observed to be dose dependent and improvement have been associated with reduced dosing. The mechanism leading to these changes is not fully understood. Use of PROGRAF with sirolimus in heart transplantation patients in a US study was associated with increased risk of renal function impairment, and is not recommended. Patients with impaired renal function should be monitored closely as the dosage of tacrolimus may need to be reduced.

Care should be taken in using tacrolimus with other nephrotoxic drugs. In particular, tacrolimus should not be used simultaneously with cyclosporin. Tacrolimus or cyclosporin should be discontinued at least 24 hours prior to initiating the other. In the presence of elevated tacrolimus or cyclosporin concentrations, dosing with the other drug usually should be further delayed.

**Hyperkalaemia**

Mild to severe hyperkalaemia was reported in patients treated with PROGRAF, especially in patients with renal impairment. Patients may require treatment, and should avoid high dietary potassium intake. Serum potassium levels should be monitored and potassium-sparing diuretics should not be used during tacrolimus therapy.

**Anaphylaxis with IV Administration**

PROGRAF Concentrated Injection contains PEG-60 Hydrogenated Castor oil, which has been reported to cause anaphylactoid reactions. These reactions consist of flushing of the face and upper thorax, acute respiratory distress with dyspnoea and wheezing, blood pressure changes and tachycardia. Caution is therefore necessary in patients who have previously received, by intravenous injection or infusion, preparations containing PEG-60 Hydrogenated Castor Oil and in patients with an allergenic predisposition. Studies in the dog have show that the risk of anaphylaxis may be reduced by slow infusion of PROGRAF or by prior administration of an H1 antihistamine. PROGRAF or PROGRAF-XL capsules 1mg and 5mg do not contain PEG-60 Hydrogenated Castor Oil.

**Malignancies**

As with other potent immunosuppressive compounds, patients treated with tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. Exposure to sunlight and ultraviolet (UV) light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.

Lymphoproliferative disorder (LPD) related to Epstein-Barr Virus (EBV) infection has been reported in immunosuppressed organ transplant recipients. In patients switched to PROGRAF, this may be attributable to over-immunosuppression before commencing therapy with this agent. Very young (<2 years), EBV-sero-negative children have been reported to have an increased risk of developing lymphoproliferative disorders. Therefore, in this patient group, EBV serology should be ascertained before starting treatment with tacrolimus. During treatment, careful monitoring is recommended.
**Infections**

Like other immunosuppressants, tacrolimus predisposes patients to the development of a variety of bacterial, fungal, parasitic and viral infections. Oversuppression of the immune system can also increase susceptibility to opportunistic infections, sepsis and fatal infections. Among these conditions are BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.

**Hypertension**

Hypertension is a common adverse effect of tacrolimus therapy. Antihypertensive therapy may be required; the control of blood pressure can be accomplished with any of the common antihypertensive agents. Since tacrolimus may cause hyperkalemia, potassium-sparing diuretics should be avoided. While calcium-channel blocking agents can be effective in treating Prograf-associated hypertension, care should be taken since interference with tacrolimus metabolism may require a dosage reduction.

**Myocardial Hypertrophy**

Ventricular hypertrophy or hypertrophy of the septum, reported as cardiomyopathies have been observed in a few cases in association with administration of PROGRAF. Most of these have been reversible, occurring primarily in patients having tacrolimus blood trough levels higher than the recommended level. Mean tacrolimus whole blood trough concentrations during the period prior to diagnosis of myocardial hypertrophy in 20 patients with pre and post treatment echo cardiograms ranged from 10.6 to 53.3 ng/mL in infants (N= 10, age 0.4 to 2 years), 4.0 to 45.7 ng/mL in children (N= 7, age 2 to 15 years) and 10.9 to 24.3 ng/mL in adults (N= 3, age 37 to 45 years). Other factors observed to increase the risk of these clinical conditions are, for example, previously existing heart diseases, corticosteroid usage, hypertension, renal or hepatic dysfunction, and fluid overload. Accordingly, high-risk patients should be monitored, e.g., with echocardiography or ECG. If abnormalities develop, dose reduction of tacrolimus therapy, or change of treatment to other immunosuppressive agent should be considered.

**Conversion between agents**

**Conversion between tacrolimus formulations**

Various formulations of tacrolimus are available. Medication errors have resulted in incorrect dosing or unsupervised switching between tacrolimus formulations. This has led to serious adverse events, including graft rejection, or other side effects which could be a consequence of either under exposure or over exposure to tacrolimus. Therefore it is appropriate to prescribe and dispense tacrolimus by tradename, taking care to specify appropriate daily dosing (e.g. PROGRAF - twice daily, PROGRAF-XL – once daily). It should be emphasised that patients, once titrated to an effective dose of a particular formulation of tacrolimus, should not be changed to another formulation of tacrolimus without blood trough level monitoring, clinical assessment and re-titration (see DOSAGE AND ADMINISTRATION).

**Conversion with cyclosporin**

Tacrolimus should not be administered concurrently with cyclosporin as the half-life of the latter may be increased. Synergistic/additive nephrotoxic effects can also occur. Care should be taken when administering tacrolimus to patients who have previously received cyclosporin and when converting patients from cyclosporin- to tacrolimus -based therapy. It is recommended that cyclosporin blood levels are monitored prior to the administration of PROGRAF or PROGRAF-XL. The most appropriate time to initiate PROGRAF or PROGRAF-XL therapy should be based upon information on cyclosporin blood levels and the clinical condition of the patient. Dosing may be delayed in the presence of elevated cyclosporin levels. Monitoring of cyclosporin blood levels should be continued following conversion as the
clearance of cyclosporin may be affected. A 24 hour interval between stopping cyclosporin and starting PROGRAF or PROGRAF-XL has been commonly used.

Patients switched to PROGRAF or PROGRAF-XL rescue therapy should not be given anti-lymphocyte treatment concomitantly.

Driving / Operation of Machinery
Tacrolimus may cause visual and neurological disturbances. Patients treated with tacrolimus who are affected by such disorders should not drive a car or operate dangerous machinery.

Effects on fertility
Oral treatment of rats with tacrolimus had no effect on male or female fertility at oral doses up to 3.2 mg/kg (blood exposure was less than the exposure achieved after the maximum recommended clinical dose, 0.3 mg/kg, based on AUC).

Use in Pregnancy
Category C
In reproduction studies in rats and rabbits, adverse effects on the fetus were observed mainly at dose levels that were toxic to the dams. Tacrolimus at oral doses of 0.32 mg/kg during organogenesis in rabbits was associated with maternal toxicity as well as an increase in the incidence of abortions. At 1.0 mg/kg increased incidences of malformations and developmental variations were also seen (a dose of 1.0 mg/kg resulted in a blood exposure approximately equivalent to the exposure achieved after the maximum recommended clinical dose, 0.3mg/kg, based on AUC). Tacrolimus, at oral doses of 3.2mg/kg during organogenesis in rats, was associated with maternal toxicity and caused an increase in late resorptions, decreased numbers of live births and decreased pup weight and viability (a dose of 3.2 mg/kg resulted in a blood exposure less than the exposure achieved after the maximum recommended clinical dose, 0.3 mg/kg, based on AUC). Tacrolimus given orally at 1.0 and 3.2 mg/kg to pregnant rats after organogenesis and during lactation was associated with reduced pup weights. No reduction in male or female fertility was evident.

There are no adequate and well-controlled studies in pregnant women. The use of tacrolimus during pregnancy has been associated with neonatal hyperkalaemia and renal dysfunction. Tacrolimus should be used during pregnancy only if the potential benefit to the mother justifies potential risk to the fetus.

Use in Lactation
Tacrolimus is excreted into breast milk. It is therefore recommended that mothers should not breast-feed while receiving tacrolimus.

Carcinogenicity
Tacrolimus did not show any tumourigenic effects in long term carcinogenicity studies using the mouse and rat. The maximum dose tested in the rat resulted in a blood exposure less than, and a plasma exposure 1.4 times the exposure achieved after the maximum recommended clinical dose, 0.3 mg/kg, based on AUC. In mice the maximum dose was 0.8 times the recommended clinical dose based on body surface area. Patients receiving long-term immunosuppressive therapy are at an increased risk of developing lymphomas and other malignancies (see PRECAUTIONS, Malignancies).

Genotoxicity
No evidence of genotoxicity was seen in a series of assays for gene mutations and clastogenicity. Tacrolimus did not cause unscheduled DNA synthesis in rodent hepatocytes but high concentrations of tacrolimus have been reported to increase the frequency of sister chromatid exchanges in human lymphocytes in vitro.
INTERACTIONS WITH OTHER MEDICINES

Metabolic Interactions

Systemically available tacrolimus is metabolised by hepatic CYP3A4. There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall. Concomitant use of drugs or herbal remedies known to inhibit or induce CYP3A4 may affect the metabolism of tacrolimus and thereby increase or decrease tacrolimus blood levels. It is therefore recommended to monitor tacrolimus blood levels whenever drugs which have the potential to alter CYP3A metabolism are used concomitantly and to adjust the tacrolimus dose as appropriate in order to maintain similar tacrolimus exposure.

Inhibitors of Metabolism

Clinically the following substances have been shown to increase tacrolimus blood levels:
Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole and voriconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir), HCV protease inhibitors (e.g. telaprevir, boceprevir) and amiodarone. Concomitant use of these drugs may require decreased tacrolimus doses in nearly all patients.
Weaker interactions have been observed with clotrimazole, clarithromycin, josamycin, nifedipine, nicardipine, diltiazem, verapamil, danazol, ethinylestradiol, omeprazole and nefazodone.
The herbal remedy schisandra sphenanthera extract inhibits CYP3A4 and may increase the blood levels of tacrolimus. 
In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethindrone, quinidine, tamoxifen, (triacetyl)oleandomycin.
Grapefruit juice has been reported to increase the blood level of tacrolimus and should therefore be avoided.
Lansoprazol and cyclosporin may potentially inhibit CYP3A4-mediated metabolism of tacrolimus and thereby increase tacrolimus whole blood concentrations.

Inducers of Metabolism

Clinically the following substances have been shown to decrease tacrolimus blood levels:
Strong interactions have been observed with rifampicin, phenytoin or St John’s Wort (Hypericum perforatum) which may require increased tacrolimus doses in almost all patients.
Clinically significant interactions have also been observed with phenobarbital. Maintenance doses of corticosteroids have been shown to reduce tacrolimus blood levels.
High dose prednisolone or methylprednisolone administered for the treatment of acute rejection have the potential to increase or decrease tacrolimus blood levels.
Carbamazepine, metamizole and isoniazid have the potential to decrease tacrolimus concentrations.

Effect of Tacrolimus on the Metabolism of Other Drugs

Tacrolimus is a known CYP3A4 inhibitor; thus concomitant use of tacrolimus with drugs known to be metabolised by CYP3A4 may affect the metabolism of such drugs.
The half-life of cyclosporin is prolonged when tacrolimus is given concomitantly. In addition, synergistic/additive nephrotoxic effects can occur. For these reasons, the combined administration of cyclosporin and tacrolimus is not recommended and care should be taken when administering tacrolimus to patients who have previously received cyclosporin.
Tacrolimus have been shown to increase the blood level of phenytoin.
As tacrolimus may reduce the clearance of steroid-based contraceptives leading to increased hormone exposure, particular care should be exercised when deciding upon contraceptive measures.
Limited knowledge of interactions between tacrolimus and statins is available. Available data suggests that the pharmacokinetics of statins are largely unaltered by the co-administration of tacrolimus. Animal data have shown that tacrolimus could potentially decrease the clearance and increase the half-life of pentobarbital and antipyrine.

Other potential interactions that may increase systemic exposure of tacrolimus:
- Prokinetic agents such as metoclopramide and cisapride.
- Cimetidine.
- Magnesium-aluminum-hydroxide.

Other Interactions which have led to Clinically Detrimental Effects
Concurrent use of tacrolimus with drugs known to have nephrotoxic or neurotoxic effects may increase these effects (e.g. aminoglycosides, gyrase inhibitors, vancomycin, cotrimoxazole, NSAIDs, ganciclovir or aciclovir).
Enhanced nephrotoxicity has been observed following the administration of amphotericin B and ibuprofen in conjunction with tacrolimus.
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene or spironolactone) should be avoided.
Immunosuppressants may affect the response to vaccination and vaccination during treatment with tacrolimus may be less effective. The use of live attenuated vaccines should be avoided.

Protein Binding Considerations
Tacrolimus is extensively bound to plasma proteins. Possible interactions with other drugs known to have high affinity for plasma proteins should be considered (e.g. NSAIDs, oral anticoagulants or oral antidiabetics).

ADVERSE EFFECTS
The adverse drug reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medications.

The most commonly reported adverse drug reactions (occurring in > 10% of patients) are tremor, renal impairment, hyperglycaemic conditions, diabetes mellitus, hyperkalaemia, infections, hypertension and insomnia.

Many of the adverse drug reactions stated below are reversible and/or respond to dose reduction. Oral administration appears to be associated with a lower incidence of adverse drug reactions compared with intravenous use. Adverse drug reactions are listed below in descending order by frequency of occurrence: very common (>1/10); common (>1/100, <1/10); uncommon (>1/1,000, <1/100); rare (>1/10,000, <1/1,000); very rare (<1/10,000, including isolated reports).

Infections and infestations
As is well known for other potent immunosuppressive agents, patients receiving tacrolimus are frequently at increased risk for infections (viral, bacterial, fungal, protozoal). The course of pre-existing infections may be aggravated. Both generalised and localised infections can occur.
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including tacrolimus.
Neoplasms benign, malignant and unspecified

Patients receiving immnosuppressive therapy are at increased risk of developing malignancies. Benign as well as malignant neoplasms including EBV-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.

Blood and lymphatic system disorders

common: anaemia, leukopenia, thrombocytopenia, leukocytosis, red blood cell analyses abnormal
uncommon: coagulopathies, coagulation and bleeding analyses abnormal, pancytopenia, neutropenia
rare: thrombotic thrombocytopenic purpura, hypoprothrombinaemia
unknown frequency: agranulocytosis, haemolytic anaemia, pure red cell aplasia (observed during post-marketing)

Immune system disorders

Allergic and anaphylactoid reactions have been observed in patients receiving tacrolimus (see PRECAUTIONS).

Endocrine disorders

rare: hirsutism

Metabolism and nutrition disorders

very common: hyperglycaemic conditions, diabetes mellitus, hyperkalaemia
common: hypomagnesaemia, hypophosphataemia, hypokalaemia, hypocalcaemia, hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, anorexia, metabolic acidoses, hyperlipidaemia, hypercholesterolaemia, hypertriglyceridaemia, other electrolyte abnormalities
uncommon: dehydration, hypoproteinaemia, hyperphosphataemia, hypoglycaemia

Psychiatric disorders

very common: insomnia
common: anxiety symptoms, confusion and disorientation, depression, depressed mood, mood disorders and disturbances, nightmare, hallucination, mental disorders
uncommon: psychotic disorder

Nervous system disorders

very common: tremor, headache
common: seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, writing impaired, nervous system disorders
uncommon: coma, central nervous system haemorrhages and cerebrovascular accidents, paralysis and paresis, encephalopathy, speech and language abnormalities, amnesia
rare: hypertonia
very rare: myasthenia

Eye disorders

common: vision blurred, photophobia, eye disorders
uncommon: cataract
rare: blindness

Ear and labyrinth disorders

common: tinnitus
uncommon: hypoacusis
rare: deafness neurosensory
very rare: hearing impaired

Cardiac disorders
common: ischaemic coronary artery disorders, tachycardia
uncommon: ventricular arrhythmias and cardiac arrest, heart failures, cardiomyopathies, ventricular hypertrophy, supraventricular arrhythmias, palpitations, ECG investigations abnormal, heart rate and pulse investigations abnormal, QT prolongation, Torsades de pointes.
rare: pericardial effusion
very rare: echocardiogram abnormal

Vascular disorders
very common: hypertension
common: haemorrhage, thrombembolic and ischaemic events, peripheral vascular disorders, vascular hypotensive disorders
uncommon: infarction, venous thrombosis deep limb, shock

Respiratory, thoracic and mediastinal disorders
common: dyspnoea, parenchymal lung disorders, pleural effusion, pharyngitis, cough, nasal congestion and inflammations
uncommon: respiratory failures, respiratory tract disorders, asthma
rare: acute respiratory distress syndrome

Gastrointestinal disorders
very common: diarrhoea, nausea
common: gastrointestinal inflammatory conditions, gastrointestinal ulceration and perforation, gastrointestinal haemorrhages, stomatitis and ulceration, ascites, vomiting, gastrointestinal and abdominal pains, dyspeptic signs and symptoms, constipation, flatulence, bloating and distension, loose stools, gastrointestinal signs and symptoms
uncommon: ileus paralytic, peritonitis, acute and chronic pancreatitis, blood amylase increased, gastrooesophageal reflux disease, impaired gastric emptying
rare: subileus, pancreatic pseudocyst

Hepatobiliary disorders
very common: liver function test abnormal
common: bile duct disorders, cholestasis and jaundice, hepatocellular damage and hepatitis
rare: hepatic artery thrombosis, venoocclusive liver disease
very rare: hepatic failure

Skin and subcutaneous disorders
common: pruritus, rash, alopecias, acne, sweating increased
uncommon: dermatitis, photosensitivity
rare: toxic epidermal necrolysis (Lyell's syndrome)
very rare: Stevens Johnson syndrome

Musculoskeletal and connective tissue disorders
common: arthralgia, muscle cramps, pain in limb, back pain
uncommon: joint disorders

Renal and urinary disorders
very common: renal impairment
common: renal failure, renal failure acute, oliguria, renal tubular necrosis, nephropathy toxic, urinary abnormalities, bladder and urethral symptoms
uncommon: anuria, haemolytic uraemic syndrome
very rare: nephropathy, cystitis haemorrhagic

**Reproductive system and breast disorders**
uncommon: dysmenorrhoea and uterine bleeding

**General disorders and administration site conditions**
common: asthenic conditions, febrile disorders, oedema, pain and discomfort, blood alkaline phosphatase increased, weight increased, body temperature perception disturbed
uncommon: multi-organ failure, influenza like illness, temperature intolerance, chest pressure sensation, feeling jittery, feeling abnormal, blood lactate dehydrogenase increased, weight decreased
rare: thirst, fall, chest tightness, mobility decreased, ulcer
very rare: fat tissue increased

**Injury, poisoning and procedural complications**
common: primary graft dysfunction

Medication errors, including inadvertent, unintentional or unsupervised substitution of immediate- or prolonged-release tacrolimus formulations, have been observed. A number of associated cases of transplant rejection have been reported (frequency cannot be estimated from available data).

**DOSAGE AND ADMINISTRATION**

The dosage recommendations given below for oral and intravenous administration should act as a guideline. PROGRAF and PROGRAF-XL doses should be adjusted according to individual patient requirements.

If allograft rejection or adverse events occur, alteration in the immunosuppressive regimen should be considered.

**Method of Administration**

It is recommended that the oral daily dose of PROGRAF be administered as two divided doses, in the morning and in the evening.

It is recommended that the oral daily dose of PROGRAF-XL be administered once daily in the morning.

PROGRAF and PROGRAF-XL capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximum absorption (see under Pharmacokinetics).

PROGRAF and PROGRAF-XL capsules should be taken immediately following removal from the blister. The capsules should be swallowed with fluid (preferably water).

Oral administration of PROGRAF or PROGRAF-XL should commence as soon as practicable. In some transplantation patients, therapy has commenced orally by administering the PROGRAF capsule contents suspended in water via an intranasal gastric tube.

PROGRAF Concentrated Injection should be diluted in 5% glucose solution in polyethylene or glass bottles or in 0.9% Sodium Chloride Injection solution in polyethylene bottles. The concentration of a solution for final infusion produced in this way should be in the range 0.004 - 0.1 mg/ml. The solution should not be given as a bolus.
**Liver Transplantation:**

Oral tacrolimus therapy should commence at 0.10-0.20 mg/kg/day administered as two divided doses for PROGRAF or as a total daily dose for PROGRAF-XL. Administration should start approximately 6 hours after the completion of liver transplant surgery. If the clinical condition of the patient does not allow for oral dosing then intravenous tacrolimus therapy should be initiated as a continuous 24 hour infusion, at 0.01 to 0.05 mg/kg/day.

**Kidney Transplantation:**

Oral tacrolimus therapy should commence at 0.15-0.30 mg/kg/day administered as two divided doses for PROGRAF or as a total daily dose for PROGRAF-XL. Administration should start within 24 hours of kidney transplant surgery. If the clinical condition of the patient does not allow for oral dosing then intravenous tacrolimus therapy should be initiated as a continuous 24 hour infusion, at 0.04 to 0.06 mg/kg/day.

**Lung Transplantation:**

Oral tacrolimus therapy should commence at 0.10-0.30 mg/kg/day administered as two divided doses for PROGRAF or as a total daily dose for PROGRAF-XL. Administration should start within 24 hours of lung transplant surgery. If the clinical condition of the patient does not allow for oral dosing then intravenous tacrolimus therapy should be initiated as a continuous 24 hour infusion, at 0.01-0.05 mg/kg/day.

**Heart Transplantation:**

Oral tacrolimus therapy should commence at 0.075 mg/kg/day administered as two divided doses for PROGRAF or as a total daily dose for PROGRAF-XL. Administration should start within 24 hours of heart transplant surgery. If the clinical condition of the patient does not allow for oral dosing then intravenous tacrolimus therapy should be initiated as a continuous 24 hour infusion, at 0.01-0.02 mg/kg/day.

**Further information for all indications follows:**

**Children**

Higher mg/kg doses may be required in children compared with adults to achieve the same tacrolimus blood concentration. It is recommended that the initial intravenous dose if needed should be 0.05-0.06mg/kg/day: initial oral doses should be 0.15-0.30mg/kg/day as two divided doses.

**Therapy Dose Levels for Kidney, Liver, Lung or Heart Allograft Rejection Resistant to Existing Immunosuppressive Regimens**

In patients experiencing rejection episodes, which are unresponsive to conventional immunosuppressive therapy, PROGRAF and PROGRAF-XL treatment should begin with the initial dose recommended for primary immunosuppression in that particular allograft.

**Conversion**

**Conversion of PROGRAF-Treated Patients to PROGRAF-XL**

Allograft transplant patients maintained on twice daily PROGRAF capsules dosing requiring conversion to once daily PROGRAF-XL should be converted on a 1:1 (mg:mg) total daily dose basis. PROGRAF-XL should be administered in the morning. Following conversion, tacrolimus trough levels should be monitored and if necessary dose adjustments made to maintain similar systemic exposure.

In stable patients converted from PROGRAF (twice daily) to PROGRAF-XL (once daily) on a 1:1 (mg:mg) total daily dose basis, the systemic exposure to tacrolimus (AUC_{0-24}) for PROGRAF-XL was approximately 10% lower than that for PROGRAF. The relationship between tacrolimus trough levels (C_{24}) and systemic exposure (AUC_{0-24}) for PROGRAF-XL is similar to that of PROGRAF. When converting from PROGRAF capsules to PROGRAF-XL
tacrolimus trough levels should be measured prior to conversion and within two weeks after conversion. Dose adjustments should be made to ensure that similar systemic exposure is maintained.

In de novo kidney and liver transplant patients $AUC_{0-24}$ of tacrolimus for PROGRAF-XL on Day 1 was 30% and 50% lower respectively, when compared with that for Prograf at equivalent doses. By Day 4, systemic exposure as measured by trough levels is similar for both kidney and liver transplant patients with both formulations. Careful and frequent monitoring of tacrolimus trough levels is recommended in the first two weeks post-transplant with PROGRAF-XL to ensure adequate drug exposure in the immediate post-transplant period. As tacrolimus is a substance with low clearance, adjustments to the PROGRAF-XL dose regimen may take several days before steady state is achieved.

**Conversion from cyclosporin to PROGRAF or PROGRAF-XL**

Care should be taken when converting patients from cyclosporin-based to tacrolimus-based therapy (see PRECAUTIONS and Interactions with Other Drugs). Tacrolimus-based therapy should be initiated after considering cyclosporin blood concentrations and the clinical condition of the patient. Dosing should be delayed in the presence of elevated cyclosporin blood levels. In practice, tacrolimus-based therapy has been initiated 12-24 hours after discontinuation of cyclosporin. Monitoring of cyclosporin blood levels should be continued following conversion as the clearance of cyclosporin might be affected.

**Conversion between tacrolimus formulations**

Differences between oral formulations of tacrolimus can lead to important differences in systemic exposure to tacrolimus. Inadvertent or unsupervised switching between formulations is unsafe and could lead to graft rejection or increased incidence of side effects. Therefore it is appropriate to prescribe and dispense tacrolimus by tradename, taking care to specify appropriate daily dosing (e.g. PROGRAF - twice daily, PROGRAF-XL – once daily). Patients must only be switched from one tacrolimus formulation to another under the close supervision of a transplant specialist.

**Dose adjustments in special populations**

**Elderly**

Experience in the elderly is limited. There is no evidence presently available to suggest that doses should be altered in elderly patients.

**Patients with Renal Impairment**

No dose adjustment is required. However, careful monitoring of renal function is recommended.

**Patients with Liver Impairment**

Tacrolimus is extensively metabolised by the liver. In patients with liver impairment dose reduction is recommended.

Tacrolimus is normally administered together with other immunosuppressive drugs. In isolated cases, successful maintenance therapy with tacrolimus alone has been described. Tacrolimus should not be given concurrently with cyclosporin.

**Race**

In comparison to Caucasians, black patients may require higher tacrolimus doses to achieve similar trough levels.

**Gender**

There is no evidence that male and female patients require different doses to achieve similar trough levels.
Monitoring of tacrolimus WHOLE BLOOD trough concentrations in conjunction with other laboratory and clinical parameters is considered an essential aid to patient management for the evaluation of rejection, toxicity, dose adjustments and compliance. Factors influencing frequency of monitoring include but are not limited to hepatic or renal dysfunction, the addition or discontinuation of potentially interacting drugs and the post-transplant time. Blood trough concentration monitoring is not a replacement for renal or liver function monitoring and tissue biopsies.

Various assays have been used to measure blood or plasma concentrations of tacrolimus. Comparison of the concentrations in published literature to patient concentrations should be made with care and knowledge of the assay methods employed.

Trough blood concentrations should be measured at 12 hours after a PROGRAF dose or 24 hours after a PROGRAF-XL dose. The majority of patients (adults and children) can be successfully managed if the trough blood concentrations are maintained within the following range:

- Liver transplant: 5-20 ng/mL for the first 3 months, 5-15 ng/mL thereafter.
- Kidney transplant: 10-20 ng/mL for the first 3 months, 5-15 ng/mL thereafter
- Heart transplant: 10-20 ng/mL for the first 3 months, 5-15 ng/mL thereafter
- Lung transplant: 10-20 ng/mL for the first month, then 5-15 ng/mL thereafter

During the first months post-transplant, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ECG, visual status, blood glucose levels, electrolytes (particularly potassium), creatinine, BUN, urinary output, haematology parameters, coagulation values, and liver and renal function tests. If clinically relevant changes are seen, adjustment of the immunosuppressive regimen should be considered.

Post-transplant improvement in the condition of the patient may alter the pharmacokinetics of PROGRAF and PROGRAF-XL. This should be considered when deciding upon a maintenance regimen.

Compatibility
Tacrolimus is incompatible with PVC plastics. Tubing, syringes, and other equipment used to administer tacrolimus should not contain PVC.

OVERDOSAGE

Experience of overdosage is limited.

Early clinical experience (when initial induction doses were 2-3 times greater than those currently recommended) suggested that symptoms of overdosage may include glucose intolerance, renal, neurological and cardiac disorders, hyperkalaemia and hypertension. Over immunosuppression may increase risk of severe infections.

Liver function clearly influences all pre- and post-operative pharmacokinetic variables. Patients with failing liver grafts or those switched from other immunosuppressive therapy to PROGRAF should be monitored carefully to avoid overdosage.

No specific antidote to tacrolimus therapy is available. If overdosage occurs, general supportive measures and symptomatic treatment should be conducted.

Based on the poor aqueous solubility and extensive erythrocyte and plasma protein binding, it is anticipated that PROGRAF will not be dialysable. Data on haemoperfusion are not
available. Activated charcoal may reduce absorption of the drug if given within one or two hours after ingestion. In patients who are not fully conscious or have impaired gag reflex, consideration should be given to administering activated charcoal via a nasogastric tube, once the airway is protected.

PRESENTATION AND STORAGE CONDITIONS

**PROGRAF Capsules**

PROGRAF capsules 0.5 mg: light yellow hard gelatine capsules with ‘0.5 mg’ and ‘[f]607’ printed in red. Each capsule contains 0.5 mg tacrolimus.

PROGRAF capsules 1 mg: white, hard gelatine capsules with ‘1 mg’ and ‘[f]617’ printed in red. Each capsule contains 1 mg tacrolimus.

PROGRAF capsules 5 mg: greyish-red, hard gelatine capsules with ‘5 mg’ and ‘[f]657’ printed in white. Each capsule contains 5 mg tacrolimus.

PROGRAF capsules are supplied as blister strips each containing 10 capsules packed within a protective aluminium wrapper. The 1 and 5 mg capsules should be stored below 30°C, and the 0.5 mg capsules below 25°C. After opening the aluminium wrapper, PROGRAF capsules are stable for 12 months when stored at room temperature. The blister strips should be kept in a dry place and the capsules should be left in the blister until required for use.

**PROGRAF-XL Prolonged-Release Capsules**

PROGRAF-XL 0.5 mg prolonged-release capsules: oblong capsules with a light yellow cap imprinted with “0.5 mg” and an orange body imprinted with “647”.

PROGRAF-XL 1 mg prolonged-release capsules: oblong capsules with a white cap imprinted with “1 mg” and an orange body imprinted with “677”.

PROGRAF-XL 5 mg prolonged-release capsules: oblong capsules with a greyish red cap imprinted with “5 mg” and an orange body imprinted with “687”.

PROGRAF-XL prolonged-release capsules are supplied as blister strips each containing 10 capsules packed within a protective aluminium wrapper. PROGRAF-XL prolonged-release capsules should be stored below 25°C. After opening the aluminium wrapper, PROGRAF-XL prolonged-release capsules are stable for 12 months when stored at room temperature. The blister strips should be kept in a dry place and the capsules should be left in the blister until required for use.

**PROGRAF Concentrated Injection**

PROGRAF Concentrated Injection 5 mg/mL: colourless, clear, sterile liquid in transparent glass ampoules. Each mL of Concentrated Injection contains 5 mg tacrolimus.

PROGRAF Concentrated Injection should be protected from light and stored below 25°C. Once an ampoule is opened, the contents should be used immediately. Following reconstitution in either 5% w/v glucose solution in polyethylene or glass containers or in 0.9% Sodium Chloride Injection in polyethylene containers, the resulting infusion mixture should be used immediately.

**Package Quantities**

<table>
<thead>
<tr>
<th>PROGRAF Capsules 0.5 mg</th>
<th>Cartons of 100 capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROGRAF Capsules 1 mg</td>
<td>Cartons of 100 capsules</td>
</tr>
</tbody>
</table>
PROGRAF Capsules 5 mg  Cartons of 50 capsules
PROGRAF XL Prolonged-Release Capsules 0.5 mg  Cartons of 30 capsules
PROGRAF XL Prolonged-Release Capsules 1 mg  Cartons of 60 capsules
PROGRAF XL Prolonged-Release Capsules 5 mg  Cartons of 30 capsules
PROGRAF Concentrated Injection 5 mg/mL  Cartons of 10 ampoules

NAME AND ADDRESS OF THE SPONSOR

JANSSEN-CILAG Pty Ltd
1-5 Khartoum Road, Macquarie Park, NSW 2113, Australia

NZ Office:
Auckland New Zealand

POISON SCHEDULE OF THE MEDICINE

Prescription Only Medicine

DATE OF APPROVAL

Date of first inclusion in the ARTG: 25 August 1997
Date of most recent amendment: 6 November 2014

© PROGRAF is a registered trademark of Astellas Pharma for tacrolimus preparations